Advanced cancer patients who have had at least 1 chemotherapy treatment are needed for a research study.

IRB/UVA Tracking #
21158
Principal Investigator
Matthew J Reilley
Contact
Sallie Mannen
Contact Email
Contact Phone
434.297.5724
Official Trial Title
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
Study Description

• The University of Virginia Cancer Center is conducting a clinical research study for participants who are adults ages 18 and over, non-small cell lung cancer, or squamous cell cancer of the head and neck. The purpose of this study to evaluate an experimental drug (tisotumab vedotin) in participants with these tumor cancer types. The experimental drug dose, safety, and the effects of the drug will be evaluated for this study.

Participation is approximately 5 months of study drug treatment and possibly longer, with a longer term follow-up via a clinic visit or a phone call to keep track of how you’re doing. Study specific test will be provided at no cost to you.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT03485209

Compensation

You will not receive compensation for this study. Reimbursement: o Up to $.17 (or the IRS medical rate for the year) for travel if you live over 50 miles away. Up to $200 for hotel stay.